Staff reviewed
DESIGN AND SAFETY CONSIDERATIONS FOR CLINICAL TRIALS INVOLVING IBOGAINE DRUG PRODUCTS; REQUEST FOR INFORMATION
— STAFF
Federal drug regulators have opened a public docket on the design of early-phase ibogaine trials and disclosed that the first federally funded studies of the compound in opioid use disorder and PTSD are being planned, but the notice is a request for comment and imposes no obligation on anyone treating or evaluating patients.